过去十年中对数以万计被疑为AMI的病人进行了大规模的随机、多中心溶栓试验。 以1983年为开端的GISSI-1试验的结果不仅激发了静脉内溶栓疗法的广泛应用,而且也促进了这一领域的进一步研究。为了检验不同的溶栓策略是否产生不同的临床效果,随后又进行了GISSI-2与ISIS-3试验。这两个研究均发现不同溶栓药物治疗时患者的存活率几乎相同,这大出研究者所料,也引起困惑、争论甚至紧张。研究者将这种结 In the past decade, tens of thousands of patients suspected of AMI were randomized, multicenter thrombolysis trials. The results of the GISSI-1 trial, which began in 1983, have not only stimulated the widespread use of intravenous thrombolytic therapy but have also led to further research in this area. In order to test whether different thrombolytic strategies produce different clinical effects, GISSI-2 and ISIS-3 were subsequently conducted. Both of these studies found that patients treated with different thrombolytic drugs had almost the same survival rates, which was much more likely to be expected by the investigators and caused confusion, controversy and even tension. Researchers will be such a knot